Home/Filings/4/0001209191-21-008587
4//SEC Filing

Poukalov Konstantin 4

Accession 0001209191-21-008587

CIK 0001785345other

Filed

Feb 7, 7:00 PM ET

Accepted

Feb 8, 6:08 PM ET

Size

14.6 KB

Accession

0001209191-21-008587

Insider Transaction Report

Form 4
Period: 2021-02-08
Poukalov Konstantin
Director10% Owner
Transactions
  • Conversion

    Series A Preferred Stock

    2021-02-085,883,5380 total(indirect: By funds)
    Common Stock (5,883,538 underlying)
  • Conversion

    Common Stock

    2021-02-08+13,369,72813,369,728 total(indirect: By funds)
  • Purchase

    Common Stock

    2021-02-08$16.00/sh+1,250,000$20,000,00014,619,728 total(indirect: By funds)
  • Conversion

    Series B Preferred Stock

    2021-02-087,486,1900 total(indirect: By funds)
    Common Stock (7,486,190 underlying)
Footnotes (7)
  • [F1]Each share of the Issuer's Series A preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A preferred stock had no expiration date.
  • [F2]Each share of the Issuer's Series B preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date.
  • [F3]Consists of 5,799,564 shares of common stock held by Perceptive Life Sciences Master Fund, Ltd. ("PLSMF"), 5,799,564 shares of common stock held by Perceptive Xontogeny Venture Fund, LP ("PXVF"), and 1,770,600 shares of common stock held by PX Venture (A), LLC ("PXV"). Perceptive Advisors, LLC ("Perceptive Advisors") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
  • [F4]Securities are held by PLSMF, PXVF, and PXV. Perceptive Advisors serves as the investment manager to Perceptive PLSMF, PXVF, and PXV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a Managing Director of Perceptive Advisors and may be deemed to indirectly beneficially own the securities. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
  • [F5]Securities are held by PLSMF and PXVF. Perceptive Advisors serves as the investment manager to PLSMF and PXVF. and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a Managing Director of Perceptive Advisors and may be deemed to indirectly beneficially own the securities. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
  • [F6]Consists of 2,941,769 shares of common stock issuable upon conversion of Series A preferred stock held by PLSMF and 2,941,769 shares of common stock issuable upon conversion of Series A preferred stock held by PXVF. Perceptive Advisors serves as the investment manager to PLSMF and PXVF. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
  • [F7]Consists of 2,857,795 shares of common stock issuable upon conversion of Series B preferred stock held by PLSMF, 2,857,795 shares of common stock issuable upon conversion of Series B preferred stock held by PXVF and 1,770,600 shares of common stock issuable upon conversion of Series B preferred stock held by PXV. Perceptive Advisors serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

Issuer

Landos Biopharma, Inc.

CIK 0001785345

Entity typeother

Related Parties

1
  • filerCIK 0001678736

Filing Metadata

Form type
4
Filed
Feb 7, 7:00 PM ET
Accepted
Feb 8, 6:08 PM ET
Size
14.6 KB